ProKidney Corp. filed its Form 10-Q with the U.S. Securities and Exchange Commission on August 10, 2026, reporting unaudited financial results for the quarterly period ended June 30, 2026.

Key Highlights

  • Net loss to Class A stockholders: $(28,422) thousand for the three months ended June 30, 2026, compared to $(16,552) thousand in the same period of 2025.
  • Total operating expenses: $48,523 thousand for Q2 2026, up from $39,930 thousand in Q2 2025, driven by increased research and development costs.
  • Cash and marketable securities: $74,868 thousand in cash and $106,696 thousand in marketable securities as of June 30, 2026, down from $108,537 thousand and $161,480 thousand, respectively, at December 31, 2025.
  • Loss per share: Basic and diluted net loss per Class A share was $(0.15) for Q2 2026, compared to $(0.13) for Q2 2025.
  • Total assets: $249,016 thousand as of June 30, 2026, compared to $335,574 thousand at December 31, 2025.
  • Shares outstanding: 208,926,941 Class A shares and 93,395,714 Class B shares outstanding as of August 10, 2026.

ProKidney Q2 2026: Operating Losses Widen as R&D Spending Rises

According to the filing, ProKidney Corp. (Nasdaq: PROK) recorded a net loss before noncontrolling interest of $(46,436) thousand for the three months ended June 30, 2026, compared to $(36,965) thousand in the prior-year period. For the six months ended June 30, 2026, the net loss before noncontrolling interest was $(89,057) thousand, versus $(74,917) thousand for the same period in 2025. The company reported revenue of $150 thousand for Q2 2026 and $376 thousand for the first half of 2026, compared to $221 thousand and $451 thousand, respectively, in the corresponding 2025 periods.

The filing disclosed that total operating expenses for Q2 2026 were $48,523 thousand, with research and development expenses rising to $36,095 thousand from $25,882 thousand in Q2 2025. General and administrative expenses declined to $12,428 thousand from $14,048 thousand over the same comparison. Interest income was $1,938 thousand for Q2 2026, down from $3,593 thousand in Q2 2025. For the six months ended June 30, 2026, interest income was $4,265 thousand, compared to $7,620 thousand in the prior-year period.

The condensed consolidated balance sheet as of June 30, 2026 showed total liabilities of $26,178 thousand and redeemable noncontrolling interest of $1,106,370 thousand. The accumulated deficit stood at $(1,318,294) thousand, and total stockholders' deficit was $(883,532) thousand. During the three months ended June 30, 2026, 63,387,108 shares of Class B common stock were exchanged for Class A common stock, the filing reported. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

What Was Disclosed

ProKidney Corp. disclosed unaudited financial statements for Q2 and the first half of 2026, showing widening net losses, increased research and development expenditures, and a decline in total assets compared to year-end 2025.